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Background
During 2009 South Africa experienced two epidemics of 
influenza – the first, from May to late June, due predominantly 
to seasonal influenza A (H3N2), and the second due to 
pandemic influenza A (H1N1). Both of these subtypes could 
be anticipated to cause significant illness burden during 2010: 
(i) the H3N2 virus has drifted significantly and may well be 
responsible for a major outbreak in 2010, affecting especially 
the elderly; and (ii) the pandemic influenza A (H1N1) (swine 
flu) will in all probability reappear as a dominant influenza 
strain during 2010. The impact of this is unpredictable, but it 
will in all likelihood affect younger individuals as occurred 
during 2009.
Vaccine formulation for 2010
The following strains have been recommended by the World 
Health Organization (WHO) for the 2010 Southern Hemisphere 
vaccine and will be incorporated into a trial vaccine:
•    A (H1N1): an A/California/7/2009 (H1N1)-like strain,  
15 µg HA per dose
•    A (H3N2): an A/Perth/16/2009 (H3N2)-like strain, 15 µg 
HA per dose
•   B: a B/Brisbane/60/2008-like strain, 15 µg HA per dose.
The two changes that have been brought in from the 2009 
formulation are: (i) replacement of the seasonal H1N1 subtype 
by the pandemic subtype – A/California/7/2009 (H1N1); and 
(ii) the new H3N2 strain – A/Perth/16/2009 (H3N2).
Recommendations for prioritisation of 
immunisation
The WHO Strategic Advisory Group of Experts (SAGE) as well 
as the Advisory Committee for Immunization Practices (ACIP) 
have advised with respect to immunisation against pandemic 
virus that prioritisation should take into account not only 
reduction of morbidity and mortality, especially in high-risk 
groups, but also reduction of transmission, i.e. epidemiological 
control and also protection of the integrity of the health care 
system. Experience in 2009 has taught us that in South Africa 
two specific risk groups also need special attention – pregnant 
women and people living with HIV.  A further consideration 
is that incorporation of the pandemic strain into the regular 
seasonal influenza vaccine means that both pandemic and 
regular seasonal risk groups will now need to be addressed 
in a combined recommendation.
The immunisation recommendations of the National 
Advisory Group on Immunization (NAGI) for South Africa for 
2010 are as follows in order of priority:
1.   Pregnant women – irrespective of stage of pregnancy.
2.    Persons over the age of 6 months with underlying medical 
conditions predisposing them to complications of influenza, 
including the following – chronic lung disease, chronic 
cardiac disease, chronic neurological disease, chronic renal 
disease, mild to severe diabetes and related metabolic 
conditions, persons on aspirin therapy.
3.    Front-line health care and emergency medical service 
personnel who come into direct contact with patients.
4.    HIV-infected adults with a CD4 count above 100 cells/µl 
and all HIV-infected children 6 months to 5 years of age.
5.    Caregivers of infants less than 6 months of age in day-care 
centres.
6.   All individuals over the age of 65 years.
7.   Children 6 months to 5 years of age.
8.    Persons between 5 years and 24 years of age living in 
hostels, boarding schools and similar institutional settings.
Dosage
•   Adults: 1 dose IM.
•   Children (<12 years): 1 dose IM.
•    Children <9 years who have never been vaccinated should 
receive 2 doses 1 month apart.
•    Children less than 3 years of age should receive half the 
adult dose on two occasions separated 1 month apart.
Contraindications
1.   Persons with a history of severe hypersensitivity to eggs.
2.    Persons with acute febrile illnesses should preferably be 
immunised after symptoms have disappeared.
Timing
Vaccines should be given sufficiently early to provide 
protection for the winter.  A protective antibody response takes 
about 2 weeks to develop.
Evidence of an earlier outbreak of pandemic H1N1 may 
necessitate earlier administration of vaccine.
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Antiviral chemotherapy
As yet, the pandemic influenza A (H1N1) and seasonal H3N2 
and B influenza viruses remain sensitive to oseltamivir (as well 
as zanamivir). Should the situation change, a further advisory 
will be issued. The dosages for treatment and post-contact 
prophylaxis (where indicated) are provided in Tables I and II.
For a more detailed consideration of the management of 
pandemic influenza A (H1N1) please see the Health Worker’s 
Handbook: http://www.nicd.ac.za/pubs/communique/2009/
sitrep/Revised_Health_Workers_Handbook_Pandemic_
influenza_H1N1_in_SA_19_08_2009.pdf
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Table II. Recommended dosage of antiviral agents for prophylaxis of high-risk contacts of confirmed, probable or suspected 
pandemic influenza A(H1N1) 2009 cases*
Age group Weight   Oseltamivir dosage*            Zanamivir dosage*
Adults     75 mg once a day              Two 5 mg inhalations (10 mg total) once a day 
Children  ≤15 kg    30 mg once a day
  15 - 23 kg   45 mg once a day             Two 5 mg inhalations (10 mg total) once a day 
  24 - 40 kg   60 mg once a day             (only in children aged 12 years or older)
  >40 kg   75 mg once a day
*Recommended duration of prophylaxis is 10 days. Zanamivir is only registered for children ≥12 years of age.
Table I. Recommended dosage of antiviral agents for treatment 
Age group Weight   Oseltamivir dosage*            Zanamivir dosage*
Adults     75 mg twice a day              Two 5 mg inhalations (10 mg total) twice a day 
Children  ≤15 kg    30 mg twice a day  
  15 - 23 kg   45 mg twice a day              Two 5 mg inhalations (10 mg total) twice a day 
  24 - 40 kg   60 mg twice a day              (only in children aged 12 years or older)
  >40 kg   75 mg twice a day  
*Recommended duration of treatment is 5 days. Zanamivir is only registered for children ≥12 years of age.
3 easy order options:
1. PHONE EDWARD OR CARMEN - 021 6817000
2. FAX the completed SAMF order form to 0866006218
3. EMAIL edwardm@hmpg.co.za
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The ESSENTIAL REFERENCE for every healthcare professional!
The carefully and thoroughly updated 9th edition of the South African Medicines Formulary (SAMF) is 
now available. It is your essential reference to rational, safe and cost-efficient use of  medicines. That 
is why you should not prescribe without it.
The newly published SAMF provides easy access to the latest, most scientifically accurate information 
– including full drug profiles, clinical notes and special prescriber’s points. The convenient pocket-size 
design enables you to fit it comfortably into your bag or hospital coat pocket – always at hand for ready 
reference.
WHY YOU SHOULDN’T BE WITHOUT THE SAMF 9TH EDITION
The new 9th edition of SAMF provides expanded information on key issues facing South African 
healthcare professionals today, including antiretrovirals, TB treatment guidelines, management 
guidelines for asthma and chronic heart failure, other common chronic conditions  and prescribing in 
sport.
• It presents practical, new approaches to the management of venomous bites and stings.
• It outlines extensively the acute adverse reactions to drugs of abuse, and their management. 
• It features new as well as existing drugs, indexed by both trade and generic names.
• It offers fresh insights into informed prescribing and carries cautionary guidelines on drug 
interactions and a range of special risk patients and conditions.
And, as always, you can rely on...
• the professional compilation and editing by a team from the Division of Clinical Pharmacology, 
UCT
• an independent and unbiased guide on prescribing in South Africa today
• the indication of agents included in the SA and WHO essential drug lists
• support of the SA national drug policy
• guidance for prescribing during pregnancy and lactation, and in patients with porphyria, liver 
disease and renal impairment (including tables with drug dosage adjustments); and 
• indexed and page tabs for quick and easy access to each section. 
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